GV, AbbVie Ventures and NS Investment have contributed to a series B round for the oncology drug developer, which has now raised a total of $103m.

The HLB-led group owns nearly half of vaccine product developer Immunomic Therapeutics following a $61.3m commitment this year.

Partners Innovation Fund joined Syncona to provide $20m for the neurological disease drug developer's series A round, which is sized at up to $77m.

CAS Shanghai Institutes for Biological Sciences spinout Aptbio secured funding to enhance its mass spectrometry drug screening business.

The Parkinson's disease therapy developer completed a series A round featuring QB3-aligned Mission Bay Capital.

SwanBio, based on research at Harvard Medical School, has secured a $20m extension to bring its series A round to $45m so far, with commitments to increase it to $77m.

M Ventures and Novartis Venture Fund co-led a round for the oncology drug startup that also featured fellow corporate venturing unit Pfizer Ventures.

Novartis DRX was among the investors in a $12.9m for the medical personnel database operator that lifted its overall funding close to $20m.

Dumac contributed to a round that took the total raised by the cancer screening system developer past the $130m mark.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.